Cargando…

Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective

Anemia is common in patients with cancer or with chronic kidney disease (CKD). Although the introduction of erythropoiesis-stimulating agents (ESAs) has transformed the management of anemia, their use has been complicated by a number of factors including frequent guideline updates, safety concerns a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aapro, Matti, Gascón, Pere, Patel, Kashyap, Rodgers, George M., Fung, Selwyn, Arantes, Luiz H., Wish, Jay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333861/ https://www.ncbi.nlm.nih.gov/pubmed/30687083 http://dx.doi.org/10.3389/fphar.2018.01498

Ejemplares similares

Erythropoiesis-Stimulating Agent Hyporesponsiveness and Adverse Outcomes: Guilty as Charged?
por: Wish, Jay B.
Publicado: (2020)

Will There Be a Role for a Short-Acting Biosimilar Erythropoiesis-Stimulating Agent in US Nephrology Practice?
por: Wish, Jay B.
Publicado: (2019)

Treatment of renal anemia: Erythropoiesis stimulating agents and beyond
por: Biggar, Patrick, et al.
Publicado: (2017)

Tips for erythropoiesis-stimulating agent treatment of renal anemia
por: Tomosugi, Naohisa, et al.
Publicado: (2019)

Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer
por: Aapro, M, et al.
Publicado: (2012)

Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease
por: Kim, Sun Moon, et al.
Publicado: (2016)

Factors associated with erythropoiesis-stimulating agent hyporesponsiveness anemia in chronic kidney disease patients
por: Amnuay, Kamalas, et al.
Publicado: (2019)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia
por: Pashos, Chris L., et al.
Publicado: (2011)

A nano erythropoiesis stimulating agent for the treatment of anemia and associated disorders
por: Das, Monojit, et al.
Publicado: (2022)

Mechanisms of hemoglobin cycling in anemia patients treated with erythropoiesis-stimulating agents
por: Jörg, David J., et al.
Publicado: (2023)

Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained
por: Aapro, Matti, et al.
Publicado: (2018)

Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients
por: Song, Jie, et al.
Publicado: (2023)

Effects of erythropoiesis-stimulating agents on heart failure patients with anemia: a meta-analysis
por: Zhang, Hengliang, et al.
Publicado: (2016)

Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron
por: Silverberg, Donald S, et al.
Publicado: (2014)

Treatment of Anemia in Kidney Disease: Beyond Erythropoietin
por: Wish, Jay B.
Publicado: (2021)

Pharmacovigilance in practice: erythropoiesis-stimulating agents
por: Hedenus, Michael, et al.
Publicado: (2014)

Ferric Carboxymaltose and Erythropoiesis-Stimulating Agent Treatment Reduces the Rate of Blood Transfusion in Refractory Anemia
por: Gidaro, Antonio, et al.
Publicado: (2022)

The role of biosimilars in value-based oncology care
por: Patel, Kashyap B, et al.
Publicado: (2018)

The Use of Darbepoetin to Stimulate Erythropoiesis in the Treatment of Anemia of Chronic Kidney Disease in Dogs
por: Fiocchi, E.H., et al.
Publicado: (2017)

Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience
por: Rodriguez Garzotto, Analia, et al.
Publicado: (2014)

Treatment of anemia in cancer patients undergoing chemotherapy with intravenous ferric carboxymaltose without erythropoiesis-stimulating agents
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2020)

Erythropoiesis stimulating agents: approaches to modulate activity
por: Sinclair, Angus M
Publicado: (2013)

Altitude Pre-Acclimatization with an Erythropoiesis-Stimulating Agent
por: Heldeweg, Micah L. A., et al.
Publicado: (2023)

Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy
por: Trotta, Francesco, et al.
Publicado: (2017)

Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience [Corrigendum]
Publicado: (2014)

Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial
por: Saglimbene, Valeria, et al.
Publicado: (2017)

End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia
por: Hoque, Shamia, et al.
Publicado: (2020)

Protective roles of erythropoiesis-stimulating proteins in chronic heart failure with anemia
por: ZHOU, SHUQIN, et al.
Publicado: (2014)

A budget impact analysis of the introduction of erythropoiesis stimulating agent subsequent entry biologics for the treatment of anemia of chronic kidney disease in Canada
por: Tsao, Nicole W, et al.
Publicado: (2014)

Use of erythropoiesis-stimulating agents in obese hemodialysis patients
por: Park, Sun-Hee
Publicado: (2018)

Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19
por: Fishbane, Steven, et al.
Publicado: (2020)

Efficacy and Cardiovascular Adverse Effects of Erythropoiesis Stimulating Agents in the Treatment of Cancer-Related Anemia: A Systematic Review of Randomized Controlled Trials
por: Gergal Gopalkrishna Rao, Sanjay Rao, et al.
Publicado: (2021)

Neuroimaging in Former Preterm Children Who Received Erythropoiesis Stimulating Agents
por: Phillips, Authors: John, et al.
Publicado: (2017)

Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer
por: Melosky, B.L.
Publicado: (2008)

Quantitative assessment of minimal effective concentration of erythropoiesis-stimulating agents
por: Yan, X, et al.
Publicado: (2013)

Erythropoiesis stimulating agents and reno-protection: a meta-analysis
por: Elliott, Steve, et al.
Publicado: (2017)

Inflammation and Erythropoiesis-Stimulating Agent Hyporesponsiveness: A Critical Connection
por: Shah, Hitesh H., et al.
Publicado: (2020)

Selenium Associates With Response to Erythropoiesis-Stimulating Agents in Hemodialysis Patients
por: Yasukawa, Minoru, et al.
Publicado: (2022)

Parathyroidectomy Improves the Consumption of Erythropoiesis-Stimulating Agents in Hemodialysis Patients
por: Lee, Yu-Ting, et al.
Publicado: (2022)

Expression of ABCG2 (BCRP) in mouse models with enhanced erythropoiesis
por: Latunde-Dada, Gladys O., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5jlml3golmsie79veiauh2aml7